Florent Gros

Chief Executive Officer and Founder

Florent Gros is CEO and Co-Founder of Priothera. He has held various leadership positions in venture, intellectual property and transaction matters at Nestlé, Pasteur Merieux Connaught and Novartis in Switzerland, Europe and North America. Florent is a Kaufmann Fellow, a certified European Patent Attorney, and he holds two master’s degrees, in Biotechnology Engineering and Private Law. At Novartis Venture Funds, Florent led investments and served in 17 start-up companies, of which 12 were exited. Since 2019, Florent is also Founder and CEO of Handl Therapeutics, a gene therapy company focusing on AAV-based neurodegenerative therapies.

Stephan Oehen

Chief Operating Officer and Founder

Immunologist, PhD with 21 years experience in biotech and pharma, a strong science (University Basel, University Hospital Zürich, UC San Diego), and drug development background in Autoimmunity, Transplantation and Inflammation (ATI). Stephan has an expert track record in Program Management and held several leadership positions in biotech (Cytos Biotechnology) and big pharma (Novartis Pharma). In 2006 he joined Novartis Research (NIBR) holding positions as Project Management Director ATI and Therapeutic Area Head of the Project Management Office. In his roles he managed the KRP203 program from inception to today. In 2018, he moved to Novartis Global Drug Development (Global Health) as Global Program Director (GPD) for out-partnering and as GPD of the Transplant Global Program Team.

Philippe Lievre

Chief Business Officer and Founder

A UK Pharmacist with an MBA from Temple University. Philippe started his career at Warner -Lambert and went on to Rhone-Poulenc as Director of Pharmaceutical Affairs of the Joint-Venture created with Tanabe Seiyaku. A few years later, Philippe created Tanabe Pharma in Paris and ultimately relocated to Osaka as Deputy General Manager in the Licensing and Business Department of Tanabe. Philippe joined Novartis in 2002, initially as a Marketing Manager (Transplantation Unit) in Tokyo, and later joined Novartis in Basel as an Alliance Manager for the Neuroscience Franchise. Philippe returned to Japan in 2014 to lead and reshape the Novartis Japanese BD&L organization. In 2017, Philippe joined the Basel BD&L group to head the Global Pharma Alliance Management Team. He has successfully managed many major in-licensing transactions.

Brice Suire

Chief Financial Officer and Founder

Brice has over 25 years’ financial experience in the life science sector, having worked as CFO and Financial consultant for several biotech and medtech companies including Gensight, Vivet and Oculis. Before that he worked for over 15 years at Novartis in Finance positions of increasing responsibility, including as Global Head of Finance Supply Chain Pharma. Prior to that, Brice played a significant role in establishing the Novartis Institute for Biomedical Research in Cambridge, MA, where he worked as Head of Finance for Research Collaborations and Global Head of Financial Reporting and Accounting for Research (at 6 different Novartis sites). Brice started his career with Audit Consultancy firms Mazars in Paris and London and Price Waterhouse Coopers in Madrid. He has a Master’s in Finance from Paris Dauphine, CPA, an IEP from INSEAD, and completed the Novartis Harvard Finance Leadership Program at Harvard Business School.

Elisabeth Kueenburg

Chief Medical Officer

Elisabeth Kueenburg received her Medical Degree from the University of Vienna, Austria and afterwards completed her fellowship and specialization in Internal Medicine and Hematology/Oncology. She joined industry in 2006, supporting the newly created Austrian affiliate of Celgene and became Austrian Medical Director during the period when the company was building up in Europe. She continued her career by moving across to working with the European headquarter in Switzerland in medical disease lead functions as well as co-chairing cross functional disease teams. For more than ten years, she served within Clinical Development as well as Medical Affairs. Before joining Priothera she held the position of a Clinical Development Lead. During her time at Celgene, then a BMS company, she was involved in all aspects of drug development as well as regulatory submissions in hematology.

Leadership Team

Our founders are globally acknowledged scientists and drug development leaders whose vision is to make a difference in AML patient care.

Florent Gros

Chief Executive Officer and Founder

Stephan Oehen

Chief Operating Officer
and Founder

Philippe Lievre

Chief Business Officer
and Founder

Brice Suire

Chief Financial Officer and Founder

Elisabeth Kueenburg

Chief Medical Officer

Florent Gros

Chief Executive Officer and Founder

Stephan Oehen

Chief Operating Officer and Founder

Philippe Lievre

Chief Business Officer and Founder

Brice Suire

Chief Financial Officer and Founder

Elisabeth Kueenburg

Chief Medical Officer

Leadership Team

Our founders are globally acknowledged scientists and drug development leaders whose vision is to make a difference in AML patient care.

Florent Gros

Stephan Oehen

Philippe Lievre

Brice Suire

Elisabeth Kueenburg

Contact Us

Priothera Ltd

Priothera SAS France

Florent Gros

Chief Executive Officer​ and Founder

Stephan Oehen

Chief Operating Officer and Founder

Philippe Lievre

Chief Business Officer and Founder

Brice Suire

Chief Financial Officer and Founder

Elisabeth Kueenburg

Chief Medical Officer

Leadership Team

Our founders are globally acknowledged scientists and drug development leaders whose vision is to make a difference in AML patient care.

Florent Gros

Stephan Oehen

Philippe Lievre

Brice Suire

Elisabeth Kueenburg

Chief Executive Officer and Founder